Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
And if the generics are as efficacious as the original, it spells good news for patients. While Tirzepatide currently leads the GLP-1 market in India with a 61% share, driven by the early launch momentum of Mounjaro and its dual GIP/GLP-1 mechanism, Semaglutide is rapidly gaining ground through its dual-brand strategy Ozempic for diabetes and Wegovy for obesity enabling sharper patient segmentation and expanding therapeutic adoption, said a recent analysis by Pharmarack
doi: 10.1186/s13018-023-04125-5, 96
It has been researched in Type 2 diabetes with some evidence that it can help lower blood sugars
This approval was also confirmed by ABC News reporting
US$ 23.96
US$ 22.68
US$ 21.51
